Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors

Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors

Abstract Targeting cell division by chemotherapy is a highly effective strategy to treat a wide range of cancers. However, there are limitations of many standard-of-care chemotherapies: undesirable drug toxicity, side-effects, resistance and high cost. New small molecules which kill a wide range of...

Full description

Bibliographic Details
Main Authors: Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C. Chüeh, Judy Doherty, François Vaillant, Gwo-Yaw Ho, Matthew J. Wakefield, Clare E. Weeden, Alvin Kamili, Jayne Murray, Sela T. Po’uha, Janet Weinstock, Serena R. Kane, Maree C. Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J. Kershaw, Chin Wee Tan, Helen M. Witchard, Gregor Ebert, Susan A. Charman, Ian Street, Maria Kavallaris, Michelle Haber, Jamie I. Fletcher, Marie-Liesse Asselin-Labat, Clare L. Scott, Jane E. Visvader, Geoffrey J. Lindeman, Keith G. Watson, Antony W. Burgess, Guillaume Lessene
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-020-03269-0

Internet

https://doi.org/10.1038/s41419-020-03269-0

Similar Items